Sort
16,300 grants matching “fatty liver disease”
Living Donor Liver Transplant :Short & Long-Term Impact on Donors and Recipients
$300,000Chris Freise · University Of California, San Francisco · U01 · FY2010 · DK
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$299,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2022 · DK
Development, Characterization & Commercialization of a Viably Frozen, Patient-Inclusive Hepatocellular Carcinoma Tumor Bank
$299,999Michael Briggs · Woodland Pharmaceuticals, Llc · R41 · FY2017 · CA
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes
$299,972Stanley Watowich · Ridgeline Therapeutics, Llc · R41 · FY2018 · DK
AMPK, Metabolic and Inflammatory Stress and the Endothelial Cell
$299,887Neil B Ruderman · Boston Medical Center · P01 · FY2012 · HL
AMPK, Metabolic and Inflammatory Stress and the Endothelial Cell
$299,887Neil B Ruderman · Boston Medical Center · P01 · FY2011 · HL
Accurate Point of Care Liver Disease Diagnostics
$299,857Pablo J Prado · Livivos Inc. · R43 · FY2022 · DK
A novel approach to discover selective small molecule inhibitors of FABP4 and FAB
$299,807Daniel A. Erlanson · Carmot Therapeutics, Inc. · R43 · FY2011 · DK
Molecular Determinants of Tumor Progression in A Steatolic Liver Microenvironment
$299,787David L Gorden · Vanderbilt University · U01 · FY2011 · CA
Regulation of glucose homeostasis by C/EBPB
$299,700Jacob E Friedman · University Of Colorado Denver · R01 · FY2007 · DK
Cardiovascular Disease (CVD) Phenotyping Core
$299,695Dorairaj Prabhakaran · Emory University · P01 · FY2024 · HL
Project 4: The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis
$299,661David A Brenner · University Of California, San Diego · P42 · FY2017 · ES
Project 3: Molecular and Microbial Mechanisms Leading to Triclosan Induced Liver Fibrosis
$299,660Robert H Tukey · University Of California, San Diego · P42 · FY2017 · ES
Project 1: Control of Toxin Obesity Induced Liver Fibrosis by B Cells
$299,658Michael Karin · University Of California, San Diego · P42 · FY2017 · ES
ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
$299,648Al Hawkins · Cometa Therapeutics Inc · R42 · FY2025 · DK
A Systemically Deliverable RNAi-based Approach for Alcoholic Liver Disease
$299,648Laura M Hales · Extend Biosciences, Inc. · R43 · FY2013 · AA
Melanocortin-3 Receptor Regulation of Physical Activity and Metabolism
$299,542Andrew Alistair Butler · Scripps Research Institute, The · R01 · FY2009 · DK
Discovery of novel small molecule drugs for Cushing's disease
$299,510Richard Scott Struthers · Crinetics Pharmaceuticals, Inc. · R43 · FY2017 · DK
De novo lipogenesis in the pathogenesis of non-alcoholic fatty liver disease
$299,360Jean-Marc Schwarz · Touro University Of California · R01 · FY2010 · DK
Collaborative Clinical Research on Non Alcoholic Stratohepatitis
$299,360Naga P. Chalasani · Indiana University Indianapolis · U01 · FY2015 · DK
Genetic Environmental Relationship Between Bone, Obesity and Leptin in Mice
$299,284James M. Cheverud · Washington University · R01 · FY2007 · DK
Regulation of Bile Acid Metabolism and Signaling in Metabolic Diseases
$299,228Tiangang Li · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2021 · DK
Role of Annexin-II in growth factor/co-carcinogenic effects of progastrin
$299,222Pomila Singh · University Of Texas Med Br Galveston · R01 · FY2010 · CA
Control of drug and ethanol metabolism
$299,194Gavin E Arteel · University Of Louisville · R01 · FY2006 · AA
Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease
$299,169Francisco Jose Schopfer · Furanica, Inc. · R41 · FY2023 · HL